ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

Articles | November 23, 2020

ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. Read More

Depression

Mission | November 16, 2020

Depression is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide, affecting an estimated 300 million people globally. Approximately one third of patients with major depressive disorder are diagnosed with treatment resistant depression. Symptoms vary, but generally, clinical depression is characterized by: Persistent… Read More

Substance Use Disorder

Mission | November 16, 2020

Substance Use Disorders (SUDs) and related disorders are a significant source of morbidity and mortality and pose a substantial cost to society Over 20m people live with a SUD in the U.S., and since the drug epidemic started in 1999, there have been over 900,000 overdose fatalities. For an already vulnerable population, COVID-19 severely exacerbated… Read More

Anxiety

Mission | November 16, 2020

Anxiety is considered a common aspect of life, however anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time. Anxiety disorders, which are believed to stem from a set of risk factors including genetics, neurochemistry, life experiences and personality, can have… Read More

ATAI’s Chief Scientific Officer joins leaders in psychedelic medicine at Mapping the Mind

News | November 9, 2020

Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in psychedelic medicine at the 2019 Mapping the Mind conference in Toronto. The conference, which featured speakers like Dr. David Nichols, founding president of the Heffter Insitute, and Dr. Matthew Johnson, associate director… Read More

Gender Disparities and Mental Health Risk Factors

Articles | November 8, 2020

We’re social creatures: We not only desire interaction with others but actually need it. Contact with others… Read More

Gender Disparities and Mental Health Risk Factors

Articles | November 8, 2020

Gender greatly influences the power that males and females have over socio-economic factors that influence their mental health, social position… Read More

ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

Articles | October 27, 2020

ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has… Read More

Burdens of Depression: The Individual

Articles | October 9, 2020

Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. Painful both mentally and physically,… Read More

ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout

Articles | August 25, 2020

For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with PTSD. Rick Doblin, for years psychedelic therapy’s most prominent advocate and fundraiser, and his non-profit, MAPS, have raised millions to advance clinical trials, most recently… Read More